Many sponsors already have “guidance summaries” and “playbooks.” The real problem is implementation: turning controls into configured workflows with evidence trails. That is why we use a 𝟭𝟬-𝗗𝗮𝘆 𝗟𝗮𝘂𝗻𝗰𝗵 𝗦𝗽𝗿𝗶𝗻𝘁 for obesity and glucagon-like peptide1 trials: the minimum viable deployment to go from “concept” to “running system.” In 10 days, the outputs are practical and inspection-ready:  • Risk-graded protocol audit run, with red/yellow fixes logged and owners assigned   • Critical ...

Accelsiors Cro

Defensible endpoints in obesity trials do not come from statistics alone. They come from an 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀–𝘀𝘁𝗮𝘁𝗶𝘀𝘁𝗶𝗰𝘀 𝗵𝗮𝗻𝗱𝘀𝗵𝗮𝗸𝗲 that is defined before the first participant is screened. World Health Organization guidance highlights the chronic-care reality and notes evidence gaps on discontinuation impacts. In practical trial terms, this means sponsors must prospectively define how interpretability is preserved when:  • participants discontinue treatment   • rescue or sw ...

Accelsiors Cro

Hybrid obesity trials fail for one reason: You cannot prove the data.  Common inspection vulnerabilities in hybrid and decentralized clinical trials:  • No clear source-of-truth for weight endpoints (clinic versus home used inconsistently)  • Missing chain-of-custody evidence at the vendor boundary (transfer logs, batch identifiers, mapping validation)  • Device audit trails not extractable (device identifier, timestamps, sync status)  • Vendor oversight is “assumed” (no documented key performan ...

Accelsiors Cro